Heme Iron Polypeptide (Proferrin- ES) Versus Iron Saccharate Complex (Ferrosac) for Treatment of Iron Deficiency Anemia during Pregnancy

Primary tabs

Acta Medica International,2017,4,1,56-61.
Published:November 2016
Type:Original Article

Heme Iron Polypeptide (Proferrin- ES) Versus Iron Saccharate Complex (Ferrosac) for Treatment of Iron Deficiency Anemia during Pregnancy

Ibrahim A. Abdelazim1,2*, Mohannad Abu-Faza2, Assem A. M. Elbiaa1, Hossam S. Othman2, Dareen A. Alsharif2, Walid Farok Elsawah3

1Department of Obstetrics and Gynecology, Ain Shams University, Egypt.

2Department of Obstetrics and Gynecology, Ahmadi Hospital, Kuwait.

3Department of Critical Care and Emergency, Ahmadi Hospital, Kuwait. 

Abstract:

Objectives: Anemia is one of the world’s leading causes of considerable perinatal morbidity and mortality. This study designed to compare the efficacy and safety of Heme iron polypeptide (Proferrin®-ES) versus iron saccharate complex (Ferrosac) in treatment of iron deficiency anemia during pregnancy. Methods: Two hundred and sixty (260) pregnant women with hemoglobin level below 10 gm/dl due to iron deficiency anemia were included in this study and randomized to receive either; intravenous Iron Saccharate (IV group) or oral Proferrin®-ES (PO group) for correction of iron deficiency anemia during pregnancy. Treatment efficacy checked by comparing pre-treatment values of hemoglobin, serum ferritin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and reticulocytes count by the 3-months` post-treatment values. Results: The 3- months` post-treatment hemoglobin level increased compared to the pre-treatment level without any significant difference between the two studied groups (from 8.5 ± 3.5 to 11.3 ± 1.3 gm/dl in PO group and from 8.7 ± 2.5 to 11.7 ± 0.9 gm/dl in IV group). In addition; the 3-months` post-treatment ferritin level, increased compared to the pre-treatment level without any significant difference between the two studied groups (from 19.4 ± 4.9 to 118.8 ± 7.1 ug/l in PO group and from 15.3 ± 5.6 to 122.3 ± 6.4 ug/l in IV group). 1.6% (2/124) of the studied women developed gastrointestinal intolerance and upset with oral Proferrin®-ES (insignificant difference and excluded from the study) and no other side effects recorded with oral Proferrin®-ES. Conclusion: HIP (Proferrin®-ES) is an effective, safe, well tolerable oral iron preparation as well as intravenous iron saccharate complex for treatment of iron deficiency during pregnancy; it increases the hemoglobin and replaces the depleted iron store.

The study design and the number of the studied women in each group